P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

Bibliographic Details
Main Authors:	Raija Silvennoinen, Anu Partanen, Anders Waage, Valdas Pečeliūnas, Fredrik Schjesvold, Pekka Anttila, Katarina Uttervall, Marjaana Säily, Mervi Putkonen, Kristina Carlson, Einar Haukas, Marja Sankelo, Damian Szatkowski, Markus Hansson, Anu Marttila, Per Axelsson, Ronald Svensson, Birgitta Lauri, Maija Mikkola, Conny Karlsson, Johanna Abelsson, Erik Ahlstrand, Anu Sikiö, Monika Klimkowska, Reda Matuzeviciene, Mona Hoyseter Fenstad, Sorella Ilveskero, Hareth Nahi
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000970496.55340.69

Similar Items

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
by: Anu Partanen, et al.
Published: (2024-02-01)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
by: Jiri Minarik, et al.
Published: (2021-01-01)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
by: Kazimierz Groen, et al.
Published: (2023-09-01)

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
by: K. Groen, et al.
Published: (2022-06-01)

Verification of the Design Concept on Nuts in Bolt/Nut Assembly for the Revision of ISO 898-2 and ISO 898-6
by: Masaya HAGIWARA, et al.
Published: (2007-12-01)

Malignant Myeloma in a Patient after Treatment for Osteoporosis with Teriparatide; a Rare Coincidence
by: Terje Forslund, et al.
Published: (2008-01-01)

PB2021: QUALITY OF LIFE AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD): RESULTS OF A REAL-WORLD EVIDENCE STUDY
by: T. Ionova, et al.
Published: (2022-06-01)

Roundtable International Discussion (IRD)
by: Universiti Putra Malaysia, Bahagian Komunikasi Korporat
Published: (2009)

Sweet Syndrome Associated with Ixazomib
by: İrfan Yavaşoğlu, et al.
Published: (2021-08-01)

P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
by: R. M. Rifkin, et al.
Published: (2022-06-01)

Mapping the Critical Intellectual Capital of IRD
by: Danielle Monegalha Rodrigues, et al.
Published: (2019-07-01)

Ixazomib in the treatment of relapsed multiple myeloma
by: S. V. Semochkin
Published: (2018-07-01)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
by: M. Haq, et al.
Published: (2021-09-01)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016-01-01)

Challenges, facilitators and barriers to the adoption and use of a web-based national IRD registry: lessons learned from the IRD-PT registry
by: João Pedro Marques, et al.
Published: (2022-08-01)

Livres électroniques des Éditions de l’IRD
by: Confins

Kaarel Ird ja Vanemuine nõukogude kultuuripoliitika kontekstis
by: Tiina Saluvere
Published: (2023-02-01)

Recursive stochastic algorithms for global optimization in IRdÌ³
Published: (2003)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
by: Shutan Li, et al.
Published: (2023-03-01)

Nutrient and Rainfall Additions Shift Phylogenetically Estimated Traits of Soil Microbial Communities
by: Kelly Gravuer, et al.
Published: (2017-07-01)

Ixazomib-induced Sweet’s syndrome: A case report
by: Jeanne Bellemare, et al.
Published: (2023-06-01)

Students assessment in 2nd grade mathematics study materials
by: Anu Leppävuori, et al.
Published: (2016-12-01)

Information technology-Information Resource Dictionary System (IRDS) framework
by: 8096 British Standards Institution

Metropolis-type annealing algorithms for global optimization in IRdÌ³
Published: (2003)

Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter studyResearch in context
by: Li Bao, et al.
Published: (2024-02-01)

Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib
by: Suheil Albert Atallah-Yunes, et al.
Published: (2018-01-01)

FDA approves ixazomib in combination with lenalidomide and dexamethasone for multiple myeloma
by: - -
Published: (2015-12-01)

Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy
by: Sini Luoma, et al.
Published: (2023-05-01)

IntelliRehabDS (IRDS)—A Dataset of Physical Rehabilitation Movements
by: Alina Miron, et al.
Published: (2021-04-01)

PERFORMANCE EVALUATION OF THE IRD RSUP DR. SARDJITO BUILDING TO THE INFLUENCE OF EARTHQUAKE
by: T. S.M. Aritonang, et al.
Published: (2012-02-01)

Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma
by: Hareth Nahi, et al.
Published: (2023-11-01)

P978: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
by: Z. Zhuang, et al.
Published: (2022-06-01)

P873: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: UPDATE OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
by: Zhe Zhuang, et al.
Published: (2023-08-01)

Saatesõna – Preface
by: Anu Treikelder, et al.
Published: (2016-12-01)

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
by: Selina Bühler, et al.
Published: (2023-01-01)

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
by: Roberto Mina, et al.
Published: (2021-12-01)

SENSORIMOTOR GATING AND SOCIAL BEHAVIOUR IN GTF2IRD1 KNOCKOUT MOUSE
by: Schneider, T, et al.
Published: (2011)

Sensitivity of the IRD whole-body counter for in vivo measurements in the case of accidental intakes
by: Bernardo Maranhão Dantas, et al.
Published: (2017-11-01)

P898: Comparing basic genetics knowledge between medical school students in Ecuador and students in the US
by: Badi Quinteros, et al.
Published: (2024-01-01)

Does Fruit and Vegetable Consumption During Adolescence Predict Adult Depression? A Longitudinal Study of US Adolescents
by: Erin Hoare, et al.
Published: (2018-11-01)